Target type: molecularfunction
Catalysis of the hydrolysis of a peptide bond not more than three residues from the N- or C-terminus of a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine). [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE, https://www.ebi.ac.uk/merops/about/glossary.shtml#EXOPEPTIDASE]
Serine-type exopeptidases are a class of enzymes that catalyze the hydrolysis of peptide bonds at the N-terminus of peptides or proteins. They are characterized by their active site, which contains a catalytic triad consisting of serine, histidine, and aspartate residues. This triad facilitates the removal of a single amino acid residue from the N-terminus of the peptide chain. The reaction mechanism involves the formation of a covalent intermediate between the serine residue and the carbonyl group of the peptide bond. This intermediate is then hydrolyzed, releasing the N-terminal amino acid and regenerating the enzyme. Serine-type exopeptidases are widely distributed in nature and are involved in a variety of cellular processes, including protein degradation, peptide processing, and signal transduction. They play important roles in regulating protein turnover, controlling cell growth and differentiation, and mediating immune responses. Examples of serine-type exopeptidases include aminopeptidases, carboxypeptidases, and dipeptidyl peptidases. They can exhibit different substrate specificities, depending on the residues surrounding the active site. For instance, some exopeptidases prefer to cleave peptides with specific amino acid residues at the N-terminus, while others are more promiscuous and can act on a broader range of substrates.'
"
Protein | Definition | Taxonomy |
---|---|---|
Dipeptidyl peptidase 2 | A dipeptidyl peptidase 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9UHL4] | Homo sapiens (human) |
Serine protease hepsin | A serine protease hepsin that is encoded in the genome of human. [PRO:DNx, UniProtKB:P05981] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
camostat | camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients. | benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide | anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor |
gabexate | Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin. | benzoate ester | |
nafamostat | nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic | benzoic acids; guanidines | |
leupeptin | aldehyde; tripeptide | bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor | |
5-amidinoindole | |||
dabigatran | dabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. | aromatic amide; benzimidazoles; beta-alanine derivative; carboxamidine; pyridines | anticoagulant; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; EC 3.4.21.5 (thrombin) inhibitor |
benzamidine | carboxamidinium ion | ||
valine-pyrrolidide | valine-pyrrolidide: structure given in first source | ||
sitagliptin | sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity. | triazolopyrazine; trifluorobenzene | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic |
vildagliptin | amino acid amide | ||
talabostat | talabostat: an antineoplastic agent; structure in first source | ||
nvp-dpp728 | |||
linagliptin | linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes. Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS. | aminopiperidine; quinazolines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent |
alanylpyrrolidine-boronic acid | |||
uamc00039 | UAMC00039: dipeptidyl peptidase II inhibitor; structure in first source | ||
bms 477118 | adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent | |
alogliptin | alogliptin : A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes. alogliptin: structure in first source | nitrile; piperidines; primary amino compound; pyrimidines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent |
gosogliptin | amino acid amide | ||
anagliptin | anagliptin: anagliptin hydrochloride salt is the active compound | amino acid amide | |
mk-3102 | pyrrolopyrazole | ||
rpx7009 | RPX7009: a beta-lactamase inhibitor; structure in first source |